Amneal has received the Food and Drug Administration’s approval of risperidone extended-release injectable suspension 12.5 mg/vial, 25 mg/vial, 37.5 mg/vial and 50 mg/vial, which is the generic of ...
TITUSVILLE, N.J., May 24 /PRNewswire/ --New data on INVEGA® SUSTENNA® (paliperidone palmitate), a long-acting injectable medicine for schizophrenia, and new data on RISPERDAL® CONSTA® (risperidone ...
Johnson & Johnson (NYSE: JNJ) has been one of the great health care and consumer products survivors of our lifetimes. Even the latest round of over-the-counter quality control flaws did not cripple ...
UZEDY (risperidone) extended-release injectable suspension for subcutaneous use is indicated for use every one or two months for the treatment of schizophrenia in adults. 1 This approval marks a ...
SAN FRANCISCO, May 19, 2009 – New data demonstrate that maintenance therapy with RISPERDAL® CONSTA® (risperidone) Long-Acting Treatment (RLAT) significantly delayed the time to relapse compared to ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Weekly risperidone delivered via the Lynx platform ...
An investigational long-acting antipsychotic containing risperidone, known as TV-46000, was able to significantly delay time to relapse in patients with schizophrenia, according to the phase III RISE ...
Study finds risperidone did not improve PTSD symptoms. — August 2, 2011 -- Risperidone, antipsychotic medication normally prescribed to treat symptoms of schizophrenia and bipolar disorder, may ...
Lupin has received approval from the Food and Drug Administration for risperidone for extended-release injectable suspension, 25 mg per vial, 37.5 mg per vial and 50 mg per vial, single-dose vials.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results